Table 4.
Multivariate analysis of prognostic factors correlated with PFS and OS in patients with ENKTCL
| PFS |
OS |
|||
|---|---|---|---|---|
| Variables | HR (95% CI) | p | HR (95% CI) | p |
| Location (nasal/others) | 1.65 (0.92–2.97) | 0.094 | - | - |
| PINK (2–3/0-1) | 0.19 (0.05–0.73) | 0.016 | - | - |
| Elevated LDH (yes/no) | - | - | 1.14 (0.62–2.13) | 0.670 |
| Distal LN involvement (yes/no) |
2.34 (0.77–7.08) | 0.134 | 0.69 (0.31–1.53) | 0.361 |
| Ann Arbor stage III–IV/I–II |
3.70 (1.57–8.73) | 0.003 | 2.02 (0.91–4.47) | 0.082 |
| NRI score (≥2/0-1) | 1.28 (0.68–2.42) | 0.443 | 1.77 (0.84–3.70) | 0.131 |
| Chemotherapy Non-ANT/ANT based |
0.33 (0.18–0.59) | <0.001 | 0.28 (0.15–0.53) | <0.001 |
| PD-L1/VISTA expression Type III/II/I |
1.47 (1.10–1.98) | 0.010 | 1.53 (1.10–2.12) | 0.012 |
Abbreviation: LDH, lactate dehydrogenase; LN, lymph node; NRI, nomogram-revised risk index; PINK, prognostic index of natural killer lymphoma, ANT, anthracycline, PFS, progression-free survival, OS, overall survival; HR, hazard ratio; CI, confidence interval; Type I, PD-L1low/VISTAlow; Type II, PD-L1low/VISTA,high or PD-L1high/VISTA low; Type III, PD-L1high/VISTAhigh. p-value <0.05 marked in bold font shows statistically significant.